The investment community has taken quite a fancy this week to Evaxion Biotech A/S, a Danish firm which is using its artificial intelligence-based technology platform to develop cancer immunotherapies.
Evaxion Cancer Vaccines Excite Investors
Shares in the Danish biotech have soared by 110% over plans to prioritize a novel category of AI-identified tumor antigens for its cancer vaccines.
